NCT01928030终止1 期
Pilot Phase 1-2 Investigational Study to Assess the Efficacy and Safety of Recombinant Hyaluronidase (rHUPH20) in the Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- Treatment-related Adverse Events
研究概览
简要总结
This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in patients with lymphedema.
详细描述
This is a phase 1, dose-escalation study followed by a phase 2 study.
Phase 1: rHuPH20 subcutaneously (SC) on days 1, 3, 5, and 7
Phase 2: rHuPH20 SC on days 1 to 21
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2
- •Unilateral upper limb secondary lymphedema
- •Must have the ability to understand and the willingness to sign a written informed consent document
- •Must agree to blood serum assessment including, complete blood count (CBC) with differential; comprehensive metabolic panel and serum osmolality at every sanctioned evaluation; additionally physician may require cardiac evaluation with echocardiogram, electrocardiogram, brain natriuretic peptide or urinalysis if deemed appropriate
- •Must consent to multi-bio-frequency impedance analysis (MFBIA); the details are to be covered in consent
- •Willing to sign consent for skin biopsies and phlebotomy
- •Women of child bearing potential must have a documented negative pregnancy test within 2 weeks prior to day 1 of treatment and agree to use a non-hormonal form of birth control during the duration of the trial therapy
排除标准
- •Pregnant or actively breast-feeding
- •Bilateral upper extremity edema
- •Bilateral manipulation of axilla within the last 24 months
- •Active infections
- •Receiving concomitant treatment for upper extremity lymphedema, or who have received treatment within the last 14 days
- •Known allergic or hypersensitivity reaction to rHUPH20 or any hyaluronidase extracts
- •Receiving concomitant diuretics or dihydropyridine class of calcium channel blockers; if an alternative medication is available, patient can become eligible after 3 half-lives of drug discontinued and patient remains medically stable
- •Grade 2 or greater hypo-albuminemia, serum sodium greater than 150meq/L, serum osmolality greater than 300mOsm/kg or blood urea nitrate/serum creatinine ratio greater than 25, within 7 days of screening
- •Unable or unwilling to self/home administer subcutaneous experimental drug; study nurse or physician will train individuals on proper administration techniques
- •Unwilling or incapable of maintaining a detailed log of number of injections, the date, time and site of administration
- •Active malignancy; those undergoing active treatment for malignancy in the adjuvant setting are eligible; treatment can include chemotherapy, targeted therapy or anti-hormonal therapy
- •At least 4 weeks removed from surgery or radiation in affected arm
- •Primary lymphedema; if edema can be explained by systemic or congenital illnesses, that patient will not be eligible for this study
- •Must not have any concurrent condition which in the investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol
- •Must not have received any investigational agents within 30 days prior to commencing study treatment
- •Active thrombophlebitis
- •Pulmonary edema, congestive heart failure or pulmonary embolus
结局指标
主要结局
Treatment-related Adverse Events
时间窗: Up to 1 year
Reported as any untoward medical occurrence or worsening of a pre-existing medical condition in a participant administered recombinant human hyaluronidase, and judged possibly, probably, or definitely related to treatment
次要结局
- Reduction in Forearm Volume(Up to 1 year)
研究者
Mark Pegram
Susy Yuan-Huey Hung Professor
Stanford University
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242HealthyNCT03785054Heptares Therapeutics Limited71
招募中
1 期
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple MyelomaPlasma Cell DisorderMultiple MyelomaNCT04879043Heidelberg Pharma AG78
已完成
1 期
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy AdultsCytomegalovirus InfectionsNCT05089630GlaxoSmithKline333
已完成
2 期
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type IINCT01194258Halozyme Therapeutics132
已完成
2 期
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusDiabetes Mellitus, Type 1NCT01194245Halozyme Therapeutics135